Endotracheal Articles & Analysis: Older
7 news found
N8 Medical, LLC (N8 Medical) today announced its first-in-human clinical trials of its flagship CeraShield™ endotracheal tube (CeraShield™ ETT) for intensive care unit patients expected to require mechanical ventilation for more than 48 hours. N8 Medical is encouraged by preliminary study data and believes that the CeraShield™ ETT will demonstrate safety and a ...
Synairgen plc (LSE: SNG), the respiratory company developing SNG001, a formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces that the international Phase 3 SPRINTER trial of SNG001 in patients hospitalised with COVID-19 did not meet its primary or key secondary efficacy endpoints. SNG001 demonstrated a favourable safety profile and was well ...
N8 Medical, LLC, a privately held biotechnology company, today announced that its CeraShield™ coated endotracheal tubes significantly reduced the growth of COVID-19 virus in recent testing. ...
In parallel, an application was made to the FDA for Emergency Use Authorization to employ aerFree® as an aid to intubation in patients with COVID-19. aerFree® may play an important role in this setting given its ease of use and its ability to expand the caliber of the upper airway, thereby facilitating first pass placement of endotracheal tubes and diminishing the ...
N8 Medical believes that use of the CeraShield™Endotracheal Tube may reduce this rate of mortality. “Biofilm growth on endotracheal tubes may lead to deadly secondary bacterial infections and exaggerated inflammatory responses requiring 8 to 9 days of additional mechanical ventilation. ...
N8 Medical’s CeraShield™ technology is broadly applicable to nearly all medical devices at risk for biofilm fouling, including endotracheal tubes, urinary catheters, orthopedic implants and cardiac devices. N8 Medical’s promising endotracheal tube initial clinical study results in the demanding intensive care unit environment support the ...
C. auris is able to attach to indwelling medical devices, such as endotracheal tubes and urinary catheters. To address this important problem, N8 Medical’s first application of CSA-131 is in its drug-eluting CeraShield™ endotracheal tube (ETT). ...